CM Wealth Advisors LLC Invests $850,000 in Thermo Fisher Scientific Inc. $TMO

CM Wealth Advisors LLC acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,693 shares of the medical research company’s stock, valued at approximately $850,000.

Several other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after buying an additional 288,296 shares during the period. J. Stern & Co. LLP boosted its position in Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares during the period. BlackRock Inc. purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $15,501,867,000. State Street Corp increased its holdings in shares of Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after purchasing an additional 229,630 shares during the period. Finally, Capital World Investors lifted its position in shares of Thermo Fisher Scientific by 7.0% in the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after purchasing an additional 718,669 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $586.12, for a total value of $2,700,840.96. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,493 shares of company stock valued at $37,657,681 in the last three months. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $628.24 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The stock’s 50-day moving average is $539.33 and its two-hundred day moving average is $508.86. The firm has a market cap of $232.29 billion, a P/E ratio of 33.79, a price-to-earnings-growth ratio of 2.50 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the company posted $4.28 EPS. The firm’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Analyst Ratings Changes

A number of research analysts recently commented on TMO shares. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Robert W. Baird dropped their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.